Wendy Buchi, MD
Gynecology · San Diego, CANPI 1356389688
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 337 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 41 manufacturers, the largest accounting for just 17.6% — the pattern of someone who eats at a lot of different presentations.
Across 337 payments — averaging $18.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Astellas Pharma US Inc$615
- Mayne Pharma Commercial LLC$412
- Daiichi Sankyo Inc.$365
- Bayer$319
- Sumitomo Pharma America, Inc.$270
- plus $3K from 35 others
What the payments were for
- Food & beverage$6,29199%
- Education$451%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 64 | $1,115 |
| Astellas Pharma US Inc | 26 | $615 |
| Mayne Pharma Commercial LLC | 27 | $412 |
| Daiichi Sankyo Inc. | 21 | $365 |
| Bayer | 17 | $319 |
| Sumitomo Pharma America, Inc. | 16 | $270 |
| Aspira Women's Health Inc | 7 | $261 |
| Exeltis, USA Inc. | 13 | $206 |
| Pfizer | 10 | $186 |
| Coopersurgical, Inc. | 10 | $183 |
| Amgen | 11 | $183 |
| Therapeuticsmd, Inc. | 12 | $175 |
| Shield Therapeutics Inc | 6 | $172 |
| Biogen | 6 | $152 |
| Vertical Pharmaceuticals, LLC | 8 | $145 |
| Intuitive Surgical | 1 | $144 |
| Exact Sciences | 8 | $142 |
| Organon | 7 | $130 |
| Hologic Sales And Service, LLC | 6 | $130 |
| Millicent US Inc | 7 | $125 |
| Myovant Sciences Inc. | 6 | $109 |
| Mission Pharmacal Company | 5 | $78 |
| Meditrina | 2 | $63 |
| Avion Pharmaceuticals | 4 | $61 |
| Channel Medsystems, Inc. | 3 | $60 |
| Merck | 4 | $60 |
| Teva Pharmaceuticals USA, Inc. | 3 | $55 |
| Lilly USA, LLC | 4 | $55 |
| Lupin Inc. | 4 | $53 |
| Seqirus USA Inc | 3 | $47 |
| AMAG Pharmaceuticals, Inc. | 3 | $45 |
| Evofem Biosciences, Inc. | 2 | $37 |
| Alfasigma USA, Inc. | 2 | $35 |
| Duchesnay USA Incorporated | 2 | $30 |
| Abbott | 1 | $24 |
| BD | 1 | $18 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Johnson & Johnson | 1 | $16 |
| Cumberland Pharmaceuticals, Inc. | 1 | $14 |
| Minerva Surgical, Inc | 1 | $14 |
| Ascend Therapeutics US, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$144
- OVA1$101
How this compares
$6,336 in reported general payments places this provider in the 85th percentile of 247 gynecology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 220 | $27,540 |
| EstringEstradiol | 50 | $26,710 |
| Estradiol (Twice Weekly)Estradiol | 122 | $16,270 |
| YuvafemEstradiol | 74 | $12,170 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 12 | $8,653 |
| DottiEstradiol | 60 | $8,413 |
| ImvexxyEstradiol | 14 | $7,804 |
| ProgesteroneProgesterone, Micronized | 142 | $6,610 |
| VeozahFezolinetant | 11 | $6,174 |
| Vivelle-DotEstradiol | 14 | $5,038 |
| LyllanaEstradiol | 14 | $2,007 |
| ValacyclovirValacyclovir Hcl | 29 | $1,475 |
| Estradiol-Norethindrone AcetatEstradiol/Norethindrone Acet | 12 | $1,336 |
| SynthroidLevothyroxine Sodium | 12 | $1,084 |
| Metronidazole | 16 | $636 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEstring | $186 | $26,71050 claims |
| Therapeuticsmd, Inc.Imvexxy | $175 | $7,80414 claims |
| Astellas Pharma US IncVeozah | $615 | $6,17411 claims |
| AbbVieSynthroid | $1,115 | $1,08412 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $55 | $16620 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 247 gynecology providers in California.
Other gynecology in San Diego
- Keerti GurushanthaiahSan Diego$5K
- Jon LischkeSan Diego$5K
- Erin BarcarseSan Diego$3K
- Bruce LeeMonterey$2.8M
- Barbara Levyla Jolla$719K
- Samar NahasRiverside$132K
- Aarathi CholkeriEl Segundo$128K
- Kelly WrightLos Angeles$119K
- Naphthali AlinsodLaguna Beach$108K
- Albertine OmaniOakland$70K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.